ALKERMES | ALKS - Current Assets


ALKERMES reported $1.52B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
ALKERMES USD 1.52B 164.26M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
J&J USD 59.77B 601M Jun/2026
Malin Corporation EUR 62.6M 26.7M Dec/2024
Merck USD 36.68B 1.66B Jun/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Otsuka Holdings JPY 1.63T 30.58B Jun/2026
Ovoca Bio EUR 2.07M 510K Dec/2025
Pfizer USD 41.36B 1.46B Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026